PE20050337A1 - COMPUESTOS DE OXAZOL COMO INHIBIDORES DE LA PRODUCCION DEL PEPTIDO Aß - Google Patents
COMPUESTOS DE OXAZOL COMO INHIBIDORES DE LA PRODUCCION DEL PEPTIDO AßInfo
- Publication number
- PE20050337A1 PE20050337A1 PE2004000763A PE2004000763A PE20050337A1 PE 20050337 A1 PE20050337 A1 PE 20050337A1 PE 2004000763 A PE2004000763 A PE 2004000763A PE 2004000763 A PE2004000763 A PE 2004000763A PE 20050337 A1 PE20050337 A1 PE 20050337A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- alkynyl
- alkenyl
- inhibitors
- peptide production
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical class C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- VASRJGMOUPSMKZ-UHFFFAOYSA-N 2-[[2-(3-phenoxyphenyl)acetyl]amino]pentanoic acid Chemical compound CCCC(C(O)=O)NC(=O)CC1=CC=CC(OC=2C=CC=CC=2)=C1 VASRJGMOUPSMKZ-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- -1 3,5-DIFLUOROPHENYL Chemical class 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 150000007978 oxazole derivatives Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A DERIVADOS DE OXAZOL DE FORMULA I, INCLUYENDO SUS SALES FARMACEUTICAMENTE ACEPTABLES, EN DONDE Z ES C(=O)CHR1R2, C(=S)CHR1R2, C(=O)C(=O)R1, ENTRE OTROS; R1 ES ALQUILO C1-C20, ALQUENILO C2-C20, ALQUINILO C2-C20, ALCOXI C1-C20, ENTRE OTROS; R2 ES H, OH, NH2, CH2OH, OC(=O)CH3, C(CH3)2OH, ENTRE OTROS; R3 ES ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6 o (ALQUILEN (C0-C4)-(CICLOALQUILO C3-C6)); R5 ES H, ALQUILO C1-C4, ALQUENILO C2-C4, ALQUINILO C2-C4, C(=O)(ALQUILO(C1-C4)), ARILO C6-C10, ENTRE OTROS; R6 ES H, ALQUILO C1-C4, ALQUENILO C2-C4, F, Cl, Br, I, CN, CF3, ENTRE OTROS; R7 ES H, ALQUILO C1-C20, ALQUENILO C2-C20, ALQUINILO C2-C20, ALCOXI C1-C20, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ESTER ETILICO DEL ACIDO 2-{2-[2-(3,5-DIFLUOROFENIL)-ACETILAMINO]-BUTILAMINO}-4-TRIFLUOROMETILOXAZOL-5-CARBOXILICO; (5-BENZOILOXAZOL-2-IL)-AMIDA DEL ACIDO 2-[2-(3-FENOXIFENIL)-ACETILAMINO]-PENTANOICO; (5-ACETILOXAZOL-2-IL)-AMIDA DEL ACIDO 2-[2-(3-FENOXIFENIL)-ACETILAMINO]-PENTANOICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE LA PRODUCCION DEL PEPTIDO Aß Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS Y/O NEUROLOGICOS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49288403P | 2003-08-06 | 2003-08-06 | |
| US49802803P | 2003-08-27 | 2003-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050337A1 true PE20050337A1 (es) | 2005-06-06 |
Family
ID=34197958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004000763A PE20050337A1 (es) | 2003-08-06 | 2004-08-06 | COMPUESTOS DE OXAZOL COMO INHIBIDORES DE LA PRODUCCION DEL PEPTIDO Aß |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7112599B2 (es) |
| EP (1) | EP1653952A4 (es) |
| JP (1) | JP2007501244A (es) |
| AR (1) | AR046327A1 (es) |
| BR (1) | BRPI0413349A (es) |
| CA (1) | CA2534529A1 (es) |
| MX (1) | MXPA06001480A (es) |
| PA (1) | PA8608601A1 (es) |
| PE (1) | PE20050337A1 (es) |
| SV (1) | SV2005001840A (es) |
| TW (1) | TW200510351A (es) |
| UY (1) | UY28458A1 (es) |
| WO (1) | WO2005016267A2 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005007717D1 (de) * | 2004-03-23 | 2008-08-07 | Pfizer Prod Inc | Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen |
| US20050222227A1 (en) * | 2004-04-01 | 2005-10-06 | Pfizer Inc | Oxazole-amine compounds for the treatment of neurodegenerative disorders |
| JP2009508934A (ja) * | 2005-09-22 | 2009-03-05 | ファイザー・プロダクツ・インク | 神経障害治療のためのイミダゾール化合物 |
| WO2008098857A1 (en) | 2007-02-15 | 2008-08-21 | F. Hoffmann-La Roche Ag | 2-aminooxazolines as taar1 ligands |
| EA020460B1 (ru) | 2009-01-12 | 2014-11-28 | Пфайзер Лимитед | Производные сульфонамида |
| UY34832A (es) * | 2012-05-31 | 2013-12-31 | Phenex Pharmaceuticals Ag | TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda) |
| IL304017A (en) | 2017-01-06 | 2023-08-01 | Yumanity Therapeutics Inc | Methods for treating neurological disorders |
| SG11202009280RA (en) * | 2018-03-23 | 2020-10-29 | Yumanity Therapeutics Inc | Compounds and uses thereof |
| SG11202108079RA (en) | 2019-01-24 | 2021-08-30 | Yumanity Therapeutics Inc | Compounds and uses thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| CN113651805B (zh) * | 2021-07-19 | 2023-07-25 | 安徽医科大学 | 一种1,2,4-噁二唑-吡啶类化合物及其在治疗阿尔茨海默症中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3094462A (en) * | 1961-09-18 | 1963-06-18 | Mcneilab Inc | Therapeutic reaction complex for muscle relaxation |
| US3591584A (en) * | 1968-08-27 | 1971-07-06 | Pfizer | Benzothiazine dioxides |
| GB1264258A (es) * | 1970-10-10 | 1972-02-16 | ||
| GB9320660D0 (en) * | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
| KR20000005291A (ko) * | 1996-06-25 | 2000-01-25 | 다케다 야쿠힌 고교 가부시키가이샤 | 옥사졸론 유도체 및 항-헬리코박터 파일로리 제제로서의 이의용도 |
| US20020002199A1 (en) * | 1998-03-12 | 2002-01-03 | Lone Jeppesen | Modulators of protein tyrosine phosphatases (ptpases) |
| AU4181000A (en) * | 1999-04-02 | 2000-10-23 | Du Pont Pharmaceuticals Company | Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase |
| TW593241B (en) * | 1999-04-20 | 2004-06-21 | Hoffmann La Roche | Carbamic acid derivatives |
| AR039059A1 (es) * | 2001-08-06 | 2005-02-09 | Sanofi Aventis | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
| AU2003265068A1 (en) * | 2002-10-09 | 2004-05-04 | Pfizer Products Inc. | Thiazole compounds for the treatment of neurodegenerative disorders |
| MXPA05003432A (es) * | 2002-10-09 | 2005-07-05 | Pfizer Prod Inc | Compuestos pirazoles para el tratamiento de trastornos neurodegenerativos. |
| ES2265600T3 (es) * | 2002-12-23 | 2007-02-16 | F. Hoffmann-La Roche Ag | Oxazoles como potenciadores de mglur 1. |
| CA2512602A1 (en) * | 2003-01-13 | 2004-07-29 | F. Hoffmann-La Roche Ag | Benzoxazole derivatives and their use as adenosine receptor ligands |
-
2004
- 2004-08-04 CA CA002534529A patent/CA2534529A1/en not_active Abandoned
- 2004-08-04 BR BRPI0413349-8A patent/BRPI0413349A/pt not_active IP Right Cessation
- 2004-08-04 EP EP04779943A patent/EP1653952A4/en not_active Withdrawn
- 2004-08-04 JP JP2006522669A patent/JP2007501244A/ja not_active Withdrawn
- 2004-08-04 MX MXPA06001480A patent/MXPA06001480A/es active IP Right Grant
- 2004-08-04 WO PCT/US2004/025023 patent/WO2005016267A2/en not_active Ceased
- 2004-08-05 US US10/911,869 patent/US7112599B2/en not_active Expired - Fee Related
- 2004-08-05 TW TW093123538A patent/TW200510351A/zh unknown
- 2004-08-06 PE PE2004000763A patent/PE20050337A1/es not_active Application Discontinuation
- 2004-08-06 AR ARP040102804A patent/AR046327A1/es unknown
- 2004-08-06 UY UY28458A patent/UY28458A1/es not_active Application Discontinuation
- 2004-08-06 PA PA20048608601A patent/PA8608601A1/es unknown
- 2004-08-09 SV SV2004001840A patent/SV2005001840A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0413349A (pt) | 2006-10-10 |
| US7112599B2 (en) | 2006-09-26 |
| EP1653952A2 (en) | 2006-05-10 |
| UY28458A1 (es) | 2005-03-31 |
| TW200510351A (en) | 2005-03-16 |
| WO2005016267A2 (en) | 2005-02-24 |
| PA8608601A1 (es) | 2005-03-03 |
| CA2534529A1 (en) | 2005-02-24 |
| US20050032859A1 (en) | 2005-02-10 |
| MXPA06001480A (es) | 2006-05-15 |
| AR046327A1 (es) | 2005-12-07 |
| JP2007501244A (ja) | 2007-01-25 |
| EP1653952A4 (en) | 2007-04-04 |
| SV2005001840A (es) | 2005-11-04 |
| WO2005016267A3 (en) | 2005-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050337A1 (es) | COMPUESTOS DE OXAZOL COMO INHIBIDORES DE LA PRODUCCION DEL PEPTIDO Aß | |
| AU2007311087B2 (en) | Organic compounds | |
| RU2361870C2 (ru) | Новые кумарины, их карбоксамидные производные, способы получения, композиции и применение | |
| PE20040155A1 (es) | Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen | |
| PE20040650A1 (es) | Moduladores del receptor de glucocorticoides | |
| PE20030856A1 (es) | Esteres hidroxamato del acido n-(4-fenilsustituido)-antranilico | |
| PE20061305A1 (es) | Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas | |
| PE20040640A1 (es) | Compuestos de tiazol como inhibidores de la enzima gamma secretasa | |
| PE20090813A1 (es) | Inhibidores de la 11b-hidroxiesteroide-deshidrogenasa | |
| CO5700757A2 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| PE20040898A1 (es) | Nuevos compuestos derivados de pirimidina | |
| PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| PE20130149A1 (es) | Derivados de la cromenona con actividad anti-tumoral | |
| RU2010120682A (ru) | Ингибиторы гистондезацетилазы | |
| PE20150636A1 (es) | Dicianopiridinas alquilamino-sustituidas y sus profarmacos de ester de aminoacido | |
| PE20030925A1 (es) | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico | |
| PE20060589A1 (es) | FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b | |
| PE20040911A1 (es) | Derivados de 3h-quinazolin-4-ona como inhibidores selectivos de la monoaminooxidasa b | |
| PE20081796A1 (es) | Derivados de pirimidina | |
| PE20120261A1 (es) | Piperidina espiro pirrolidinona y piperidinonas sustitudos como moduladores de los receptores h3 | |
| PE20050293A1 (es) | Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos | |
| PE20090798A1 (es) | Derivados de benzotiazol como moduladores del receptor de grelina | |
| PE20090513A1 (es) | Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3 | |
| MX2024012967A (es) | Derivados de piridina para el tratamiento de los trastornos psiquiatricos | |
| NO20064951L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |